Prostate Cancer
Advertisement
The first part of five segments from the live podcast, roundtable session on radioligands.
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
The primary endpoint of rPFS was maintained in both cohorts.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer.
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024.
Dr. Gerhardt Attard discusses the benefits of the Decipher score as utilized during the STAMPEDE trial.
The Decipher score demonstrated a notable benefit in predicting patient survival rates during the STAMPEDE trial.
Dr. Gerhardt Attard provides insight on the STAMPEDE study, along with the Decipher score used during the trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.